ARTICLE | Politics, Policy & Law
White House fails to bring mid-tier biotechs to MFN table
Contrary to administration leaks, high-profile mid-sized biotechs were conspicuous by their absence at a White House press conference
September 1, 2026 12:52 AM UTC
Updated on Sep 1, 2026 at 8:04 PM UTC
The most remarkable thing about Monday’s White House most-favored nation drug pricing announcement was who wasn’t there.
After months of arm-twisting and leaks from government sources and lobbyists asserting that prominent mid-tier biopharmas were signing MFN deals, the CEO of just one U.S.-based company with a single marketed product stood behind President Donald Trump. Trump said he expects other companies to sign MFN deals...